A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · None · Prevention
Enrollment
526actual
Sites
26
Countries
Puerto Rico, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-04 | actual | When the study began enrolling |
| Primary completion | 2025-09-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-30 | actual | The whole study's end, after follow-up |
| First posted | 2025-03-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Respiratory Syncytial Virus (RSV)
Interventions
- Biological: RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE — also filed as ABRYSVO, RSVpreF, PF-06928316
- Biological: HZ/su VACCINE — also filed as SHINGRIX, RZV, HZ/su
Primary outcomes
what the primary-completion date above is the date OFGeometric Mean Ratio (GMR) of Neutralizing Titer (NTs) for RSV A and B in RSVpreF + herpes zoster subunit vaccine (HZ/su) Compared to RSVpreF Alone
measured 1 month after vaccination with RSVpreF in the RSVpreF + HZ/su coadministration group to RSVpreF alone in the sequential administration group
Anti-gE antibody concentrations expressed as Geometric Mean Concentration (GMC) ratios in RSVpreF + HZ/su Compared to HZ/su Alone
measured 1 month after the second dose of HZ/su in the RSVpreF + HZ/su coadministration group to HZ/su alone in the sequential administration group
Percentage of Participants reporting Local Reactions Within 7 Days after Vaccination
measured Within 7 Days after each vaccination (Vaccination on Day 1)
Percentage of Participants with Systemic Events Within 7 Days after Vaccination
measured Within 7 Days after each vaccination (Vaccination on Day 1)
Percentage of Participants with Adverse Events (AEs)from Vaccination through 1 Month after Vaccination
measured Within 1 Month after last vaccination
Percentage of Participants with Serious Adverse Events (SAEs) Throughout the Study
measured Within 4 Months after first study vaccination (Vaccination on Day 1)
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed